Pattern’s patent-protected immunotherapeutic, PPI-100, mobilizes innate immunity to address the immune failure underpinning cancers. PPI-100 is a recently patented second generation of an earlier product that received regulatory approval and has proven safe & efficacious for several infectious disease indications in patients. PPI-100 is readily manufacturable and can be used as a monotherapy or in combination therapy. PPI-100's Mechanism of Action entails activating dendritic cells and macrophages, thereby increasing antigen-presenting activities directed at tumor antigens and resulting in anti-cancer cytotoxic T-cells and long-term T-cell memory. Based on extensive in vivo nonclinical and supporting clinical data, Pattern's clinical development activities are focused on a large, white-space opportunity to address the overall >40% relapse rate in cancer patients 5 years following surgery. Its key upcoming milestones (targeted for Q3 2024) are the completion of the GMP manufacturing of its Phase 1 clinical material and the filing of an IND Application with the FDA, which will result in a Phase 1-ready asset. Pattern works with MD Anderson, Massachusetts General Hospital, McGill University and others.

Realist Pharma is a private immunotherapy company which products which target multiple cancers through active immune responses.

Virage is a specialized financial advisory firm focusing on the life sciences, which provides advice to companies and investors on a global basis. Virage's mandates have included helping establish & finance life sciences venture capital & private equity funds, a pharmacy acquisition vehicle and an off-balance sheet financing vehicle for a major pharmaceutical company. Additionally, it has carried out a number of financing mandates for life sciences companies.

Founded and ran iNovia Capital (formerly MSBi Capital), a leading Canadian venture capital fund with investments in the life sciences and technology sectors. iNovia now has more than US$2.4B under management.

1996-2000 Founder and Chief Operating Officer of UMDI – Mark ran University Medical Discoveries Inc. (UMDI), an early-stage life sciences venture capital fund, while serving on the Management Advisory Board of the $500M Canadian Medical Discoveries Venture Capital Fund (CMDF).2001 - Business Manager, Informatics Division – MDS Proteomics (MDS Capital-backed biotechnology & bioinformatics company).Also had an entrepreneur-in-residence role at MDS Capital as CEO of Petrovax (see below).

Co-founder and CEO of this Delaware-incorporated company focused on commercializing a novel immunotherapeutic drug, which in addition to being an effective monotherapy against a range of infectious diseases also served as a vaccine carrier for a number of innovative vaccines. In this context, negotiated significant licensing deals with two large pharma multinationals.

Was responsible for identifying and evaluating new business opportunities in the healthcare sector for the company in Canada and the US.